Mind Medicine (MindMed) Inc. (FRA:MMQ)
Germany · Delayed Price · Currency is EUR 10.53
+0.27 (2.63%)
At close: Dec 1, 2025
Mind Medicine (MindMed) Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc.
| Country | Canada |
| Industry | Pharmaceutical Preparations |
| Employees | 74 |
| CEO | Robert Barrow |
Contact Details
Address: One World Trade Center New York, British Columbia 10007 United States | |
| Phone | 212 220 6633 |
| Website | mindmed.co |
Stock Details
| Ticker Symbol | MMQ |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer |
| Brandi Roberts | Chief Financial Officer |
| Peter Mack | Chief Operating Officer |